AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%

ANGIODYNAMICS INC

2026-Q2 EPS reported -$0.42 revenue$155,144,000

Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
Raised FY26 net sales guidance to $312-314M (from $308-313M); Adj. EBITDA raised to $8-10M (from $6-10M).
CEO Jim Clemmer to retire in FY2027; board initiates search; Q2 generated $4.7M cash, debt-free balance sheet.
FDA IDE approvals for APEX-Return (AlphaVac blood management) and PAVE (AngioVac right-sided endocarditis) studies.
Federal Circuit affirmed Bard patent invalidation, eliminating $3M contingent payment obligation from prior settlement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.